Navigation Links
Catalent Provides Commercial Manufacturing of Lexicon Pharmaceuticals' Orphan Drug XERMELO™ Following FDA Approval
Date:5/9/2017

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently welcomed Lexicon Pharmaceuticals, Inc.’s announcement that its pioneering orphan drug, XERMELO™, has been approved by the U.S. Food and Drug Administration (FDA). Catalent has been working in partnership with Lexicon since 2007 to develop the drug formulation, and will be manufacturing XERMELO for commercial supply.

XERMELO (telotristat ethyl) 250 mg is a first-in-class orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

“We are pleased that the skill and expertise that our scientists have dedicated to this project for ten years has resulted in this pioneering treatment reaching the market,” commented Matthew Mollan, Catalent's General Manager at its Kansas City, Missouri site. “Catalent first partnered with Lexicon when the drug was in Phase I development, and continued to support its manufacture through to supplying launch products.”

"We are proud to have discovered this ground-breaking orphan drug, and our successful collaboration with Catalent means we are now able to make it available for the thousands of patients currently suffering from this condition,” added Lonnel Coats, Lexicon's president and chief executive officer.

Carcinoid syndrome is a rare condition that occurs in patients living with metastatic neuroendocrine tumors (mNETs) and is characterized by frequent and debilitating diarrhea that often prevents patients from leading active, predictable lives, as well as by facial flushing, abdominal pain, fatigue and, over time, heart valve damage.

Catalent undertook development and manufacture of the drug at its 450,000-square-foot Kansas City facility, where the company provides a range of fully integrated support services, from formulation development and analytical testing, to clinical and commercial scale manufacturing and packaging of various oral dose forms.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at http://www.prweb.com/releases/2017/05/prweb14316592.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Catalent to Launch Innovative Fish Oil Supplement Product at Vitafoods Europe
2. Challenges and Strategies to Automate Potency Assays to be Discussed by Catalent Expert at Upcoming CASSS Bioassays Symposium
3. Catalent Expands Kansas City Clinical Storage and Secondary Packaging Capabilities to Meet Growing Demand for Cold Chain Services
4. Catalent Wins Prestigious Clinical Supply Chain Excellence Award at BioPharma Asia Convention
5. Challenges and Innovation in Clinical Trial Supply to be Presented by Catalent Experts at Upcoming Conferences
6. Catalent to Host Workshop with Leading Biologics Experts on Advanced Protein Development and Delivery at Upcoming Drug Delivery Partnerships Conference
7. Innovative Strategies for the Development of Lipid-based Oral Medicines to be Presented by Catalent and Gattefossé at Forthcoming Workshop
8. Accelerated Biopharmaceutical Development through Strategic Analytical Partnerships to be Discussed by Catalent Expert at Upcoming WCBP Conference
9. Catalent to Develop Softgel Capsules for JOT’s Leading Orphan Disease Candidates
10. Catalent Biologics Collaborates with PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine Research and Development
11. Catalent Becomes First CDMO to Join Pharmaceutical Supply Chain Initiative: Helps Shape Better Supply Chain to Pharmaceutical and Healthcare Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2020)... ... May 29, 2020 , ... ... South Carolina conducting Phase I-IV trials, commemorated May, Mental Health Awareness Month, and ... medical advances possible. , Efforts include their #StayConnected video series raising awareness ...
(Date:5/28/2020)... ... May 28, 2020 , ... With a ... fall, operators of student housing are scrambling to implement practices that will help ... 37,000 student housing beds on 38 campuses across the country, has researched best ...
(Date:5/26/2020)... (PRWEB) , ... May 26, ... ... a previously unknown mechanism through which certain infections can impact the brain ... (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections) and PANS (Pediatric Acute-onset ...
(Date:5/25/2020)... ... 23, 2020 , ... Winemaker Grant Long Jr. is introducing three Toilet Paper ... and delicious in these complicated times,” he said, in announcing the new wines. The ... The Chardonnay and Red Wine Blend are sourced in the Napa Valley; the Grenache ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... experience of GSCG, VITA NOVAS has already gained ground with the inherited reputation ... and stimulating biological products intravenously, guaranteeing an effective way for the ingredients to ...
Breaking Medicine News(10 mins):
(Date:5/30/2020)... ... ... HealthyChildren.org, the official parenting website of the American Academy of Pediatrics (AAP), celebrates ... will receive a $200 Amazon.com* gift card. The contest begins June 15 and ends ... the event. Winners will be drawn on or about June 22, 2020. Full rules ...
(Date:5/30/2020)... , ... May 30, 2020 , ... ... dealing with a host of new issues related to COVID-19. Recently, Wellness Expert ... to help expectant moms support their pregnancy and postpartum. , A video ...
(Date:5/28/2020)... ... May 28, 2020 , ... ... products led M&S Technologies, leader and innovator in essential vision testing products, to ... Technologies ’ web-based Vision Testing has been released and considering the circumstances, could ...
Breaking Medicine Technology: